Global and genetic outlook: Future trends in diabetes burden, global epidemiology and risk factors, genetics and epigenetics evolution, type 1 diabetes immunotherapy, emerging early detection biomarkers.
Therapeutic innovations: Beta-cell regeneration advancements, new drug classes: SGLT2-I, GLP-1, dual agonists, precision medicine in diabetes care, pharmacotherapy tailoring and trials, surgery and weight-loss for remission.
Technology-driven care: AI in prediction and treatment planning, wearables and continuous glucose monitoring, closed-loop insulin delivery systems, telemedicine for remote management, big data powering diabetes research.
Holistic management approach: Addressing mental health and support, cardiovascular and kidney complication care, retinopathy and neuropathy prevention, lifestyle modification via diet and exercise, diabetes in special populations addressed.
Policy, equity, and research frontiers: Public health and prevention strategies, global policies for improved care access, tackling disparities in diabetes outcomes, landmark RCTs and their implications, exploring cancer, microbiome, and sports links.